Editor: John Lasala, MD, PhD / George D. Dangas, MD, PhD
This module illuminates the medical interventions cardiologists use to inhibit the triad of platelets, coagulation factors, and the endothelium and attenuate endovascular thrombosis. Results of clinical studies with oral antiplatelet agents in ischemic heart disease and PCI are reviewed to shed light on clinical efficacy, resistance, and allergy of anti-platelet agents. Basic pharmacologic properties and clinical results of GP IIb/IIIa inhibitors in acute coronary syndromes and PCI are then discussed. Heparins and direct anti-thrombin agents are also examined, and finally complications from all agents are carefully looked at and strategies to prevent and manage bleeding complications from anticoagulation is summarized.